<DOC>
	<DOCNO>NCT01275339</DOCNO>
	<brief_summary>Currently , aortic stenosis ( AS ) consider `` surgical disease '' medical therapy available improve clinical outcome , include symptom , time surgery , long-term survival . Thus far , randomized study involve statin promise respect slow progressive valve stenosis . Beyond valve , two common consequence aortic stenosis hypertrophic remodel left ventricle ( LV ) pulmonary venous hypertension ; associate bad heart failure symptom , increase operative mortality , bad long-term outcome . Whether alter LV structural abnormality , improve LV function , and/or reduce pulmonary artery pressure medical therapy would improve clinical outcome patient AS test . Animal model pressure overload demonstrate phosphodiesterase type 5 ( PDE5 ) inhibition influence nitric oxide ( NO ) - cyclic guanosine monophosphate ( cGMP ) signal LV favorably impact LV structure function , test human AS . Studies humans left-sided heart failure pulmonary venous hypertension show PDE5 inhibition improve functional capacity quality life , patient AS included study . The investigator hypothesize PDE5 inhibition tadalafil favorable impact LV structure function well pulmonary artery pressure . In pilot study , investigator anticipate short-term administration tadalafil patient AS safe well-tolerated .</brief_summary>
	<brief_title>Aortic Stenosis PhosphodiEsterase Type 5 iNhibition ( ASPEN ) : A Pilot Study</brief_title>
	<detailed_description>Subjects moderately severe severe aortic stenosis ( AS ) , leave ventricular hypertrophy ( LVH ) , diastolic dysfunction , preserve ejection fraction , plan aortic valve replacement next 6 month eligible randomize , double-blind , placebo-controlled , pilot study . There diabetic cohort ( n=32 ) non-diabetic cohort ( n=24 ) ; cohort randomize 1:1 tadalafil vs. placebo . During baseline study visit , follow obtain : clinical data , 6 minute walk , quality life questionnaire , blood draw , echocardiogram . A 3-day run-in occur initially assess tolerability compliance . If drug tolerate run-in period , participant randomize . An MRI also perform randomization visit . Follow-up study visit test occur 6 12 week 6 month .</detailed_description>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Patients moderate severe aortic stenosis ( AVA &lt; 1.5 cm2 ) Left ventricular hypertrophy Diastolic dysfunction evidence tissue Doppler e ' ( average septal lateral ) ≤ 7 cm/s EF ≥ 50 % None minimal symptom relate aortic stenosis ( NYHA ≤ 2 ) The subject treat physician planning valve replacement procedure occur next 6 month Ambulatory Normal sinus rhythm 18 year age old Able willing comply requirement study Need ongoing nitrate medication SBP &lt; 110mmHg MAP &lt; 75mmHg Moderately severe severe mitral regurgitation Moderately severe severe aortic regurgitation Contraindication MRI Creatinine clearance &lt; 30 mL/min Cirrhosis Pulmonary fibrosis Increased risk priapism Retinal optic nerve problem unexplained visual disturbance If subject require ongoing use alpha antagonist typically use benign prostatic hyperplasia ( BPH ) ( prazosin , terazosin , doxazosin , tamsulosin ) , SBP &lt; 120 mmHg MAP &lt; 80 mmHg exclude Need ongoing use potent CYP3A inhibitor inducer ( ritonavir , ketoconazole , itraconazole , rifampin ) Current recent ( ≤ 30 day ) acute coronary syndrome O2 sit &lt; 90 % room air Females pregnant believe may pregnant Any condition PI determine place subject increase risk likely yield unreliable data Unwilling provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Aortic valve stenosis</keyword>
	<keyword>Tadalafil</keyword>
	<keyword>Phosphodiesterase inhibitor</keyword>
	<keyword>Hypertension , pulmonary</keyword>
	<keyword>Hypertrophy , leave ventricular</keyword>
</DOC>